57 related articles for article (PubMed ID: 29497297)
1. Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.
McElroy SL; Coloma PM; Berger B; Guerdjikova AI; Joyce JM; Liebowitz MR; Pain S; Rabasa C
Int J Eat Disord; 2023 Nov; 56(11):2120-2130. PubMed ID: 37584285
[TBL] [Abstract][Full Text] [Related]
2. Exploring bi-directional impacts of Lisdexamfetamine dimesylate on psychological comorbidities and quality of life in people with Binge Eating Disorder.
Griffiths KR; Boulet S; Barakat S; Touyz S; Hay P; Maguire S; Kohn MR
J Eat Disord; 2024 Jun; 12(1):80. PubMed ID: 38872181
[TBL] [Abstract][Full Text] [Related]
3. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials.
Fornaro M; Solmi M; Perna G; De Berardis D; Veronese N; Orsolini L; Ganança L; Stubbs B
Neuropsychiatr Dis Treat; 2016; 12():1827-36. PubMed ID: 27524900
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis.
Ramakrishnan D; Farhat LC; Vattimo EFQ; Levine JLS; Johnson JA; Artukoglu BB; Landeros-Weisenberger A; Zangen A; Pelissolo A; de B Pereira CA; Rück C; Costa DLC; Mataix-Cols D; Shannahoff-Khalsa D; Tolin DF; Zarean E; Meyer E; Hawken ER; Storch EA; Andersson E; Miguel EC; Maina G; Leckman JF; Sarris J; March JS; Diniz JB; Kobak K; Mallet L; Vulink NCC; Amiaz R; Fernandes RY; Shavitt RG; Wilhelm S; Golshan S; Tezenas du Montcel S; Erzegovesi S; Baruah U; Greenberg WM; Kobayashi Y; Bloch MH
J Psychiatr Res; 2024 May; 173():387-397. PubMed ID: 38598877
[TBL] [Abstract][Full Text] [Related]
5. Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine.
Guerdjikova AI; Mori N; Casuto LS; McElroy SL
Neuropsychiatr Dis Treat; 2016; 12():833-41. PubMed ID: 27143885
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder.
Hough D; Mao AR; Aman M; Lozano R; Smith-Hicks C; Martinez-Cerdeno V; Derby M; Rome Z; Malan N; Findling RL
Ann Gen Psychiatry; 2023 Nov; 22(1):45. PubMed ID: 37932739
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.
Richards J; Bang N; Ratliff EL; Paszkowiak MA; Khorgami Z; Khalsa SS; Simmons WK
Obes Pillars; 2023 Sep; 7():100080. PubMed ID: 37990682
[TBL] [Abstract][Full Text] [Related]
8. An adapted clinical global Impression of improvement for use in Angelman syndrome: Validation analyses utilizing data from the NEPTUNE study.
Ventola P; Jaeger J; Keary CJ; Kolevzon A; Adams M; Keshavan B; Zinger-Salmun C; Ochoa-Lubinoff C
Eur J Paediatr Neurol; 2023 Nov; 47():35-40. PubMed ID: 37688937
[TBL] [Abstract][Full Text] [Related]
9. Binge Eating Disorder: A 5-Year Retrospective Study on Experimental Drugs.
Levitan MN; Papelbaum M; Carta MG; Appolinario JC; Nardi AE
J Exp Pharmacol; 2021; 13():33-47. PubMed ID: 33542663
[TBL] [Abstract][Full Text] [Related]
10. Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion.
Halseth A; Shan K; Gilder K; Malone M; Acevedo L; Fujioka K
Obes Sci Pract; 2018 Apr; 4(2):141-152. PubMed ID: 29670752
[TBL] [Abstract][Full Text] [Related]
11. Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings.
Dunlop BW; Gray J; Rapaport MH
Behav Sci (Basel); 2017 Jun; 7(3):. PubMed ID: 28653978
[TBL] [Abstract][Full Text] [Related]
12. Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder.
Siafis S; Rodolico A; Çıray O; Murphy DG; Parellada M; Arango C; Leucht S
Brain Sci; 2021 Jul; 11(7):. PubMed ID: 34356141
[TBL] [Abstract][Full Text] [Related]
13. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L
Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
[TBL] [Abstract][Full Text] [Related]
14. Screening for Binge Eating Disorder in people with obesity.
Wever MCM; Dingemans AE; Geerets T; Danner UN
Obes Res Clin Pract; 2018; 12(3):299-306. PubMed ID: 29530586
[TBL] [Abstract][Full Text] [Related]
15. A register-based case-control study of health care utilization and costs in binge-eating disorder.
Watson HJ; Jangmo A; Smith T; Thornton LM; von Hausswolff-Juhlin Y; Madhoo M; Norring C; Welch E; Wiklund C; Larsson H; Bulik CM
J Psychosom Res; 2018 May; 108():47-53. PubMed ID: 29602325
[TBL] [Abstract][Full Text] [Related]
16. Binge-eating disorder in university students: high prevalence and strong link to impulsive and compulsive traits.
Solly JE; Chamberlain SR; Lust K; Grant JE
CNS Spectr; 2023 Feb; 28(1):61-69. PubMed ID: 34658319
[TBL] [Abstract][Full Text] [Related]
17. Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.
Heal DJ; Smith SL
J Psychopharmacol; 2022 Jun; 36(6):680-703. PubMed ID: 34318734
[TBL] [Abstract][Full Text] [Related]
18. The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics.
Boswell RG; Potenza MN; Grilo CM
Clin Ther; 2021 Jan; 43(1):50-69. PubMed ID: 33257092
[TBL] [Abstract][Full Text] [Related]
19. Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies.
Citrome L; Kando JC; Bliss C
Neuropsychiatr Dis Treat; 2018; 14():537-546. PubMed ID: 29497297
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
